Faculty Bibliography

WASHINGTON - After years of recommending AZT as the first-line drug for treating the virus that causes AIDS, federal health officials are considering a change because of surprising results with other drugs. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in an interview that he planned to convene a meeting at which independent experts could decide whether AZT should remain the first choice. A large study paid for by Fauci's institute and reported last week found that AZT was less effective than another drug, didanosine, or ddI, and also less effective than combinations of AZT with either ddI or zalcitabine (ddC)

A large study paid for by Dr. Fauci's institute and reported this week found that AZT was less effective than another drug, didanosine, or ddI, and also less effective than combinations of AZT with either ddI or zalcitabine, known as ddC. The participants were randomly divided into four groups, which received AZT alone, ddI alone, a combination of ddI and AZT, or a combination of ddC and AZT. Of the participants, 57 percent had taken AZT before entering the study, and 43 percent had not. Although all three other treatments in the study fared better than AZT alone, among participants who had never taken AZT the most significant benefit was found in those who received the combination of ddC plus AZT

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in an interview that he planned to convene a meeting where independent experts could decide whether AZT should remain the first choice. A large study paid for by Fauci's institute and reported last week found that AZT was less effective than another drug, didanosine, or ddI, and also less effective than combinations of AZT with either ddI or zalcitabine (ddC)

Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, said in an interview that he planned to convene a meeting where independent experts could decide whether AZT should remain the first choice. A large study paid for by Fauci's institute and reported last week found that AZT was less effective than another drug, didanosine, or ddI, and also less effective than combinations of AZT with either ddI or zalcitabine (ddC). One part of the study showed that ddI lowered the rate of death from HIV infection to 5 per cent from 10 per cent when compared with the use of AZT alone over 147 weeks

Federal health officials warned Thursday that a drug prescribed to treat high blood pressure and heart disease should be used 'with great caution, if at all,' and that the safety of related drugs taken by millions of Americans was unclear. The warning from the National Heart, Lung and Blood Institute applied specifically to large doses of the short-acting form of nifedipine, which is marketed as Procardia by Pfizer Inc. and as Adalat by Bayer Co. Nifedipine is one of 10 drugs called calcium channel blockers that are taken to control blood pressure and relieve pains from angina

Federal health officials warned yesterday that a drug prescribed to treat high blood pressure and heart disease should be used 'with great caution, if at all,' and that the safety of related drugs taken by millions of Americans was unclear. The warning from the National Heart, Lung and Blood Institute applied specifically to large doses of the short-acting form of nifedipine, which is marketed as Procardia by Pfizer Inc. and as Adalat by Bayer Co. Nifedipine is one of 10 drugs called calcium channel blockers that are taken to control blood pressure and relieve pains from angina

Federal health officials warned Thursday that a drug prescribed to treat high blood pressure and heart disease should be used ''with great caution, if at all,'' and that the safety of related drugs taken by millions of Americans was unclear. The warning from the National Heart, Lung and Blood Institute applied specifically to large doses of the short-acting form of nifedipine, which is marketed as Procardia by Pfizer and as Adalat by Bayer. As a class, the drugs are the most widely prescribed in the United States, with 87.3 million prescriptions written last year for an estimated six million people. More than two million of the prescriptions were for the short-acting form of nifedipine

The National Heart, Lung and Blood Institute warned on Aug 31, 1995 that nifedipine, a drug prescribed to treat high blood pressure and heart disease, should be used 'with great caution, if at all,' and that the safety of related drugs taken by millions of Americans was unclear. The study is being published in the medical journal Circulation on Sep 1

Federal health officials warned yesterday that a drug prescribed to treat high blood pressure and heart disease should be used \'with great caution, if at all,\' and that the safety of related drugs taken by millions of Americans was unclear. The warning from the National Heart, Lung and Blood Institute applied specifically to large doses of the short-acting form of nifedipine, which is marketed as Procardia by Pfizer Inc. and as Adalat by Bayer Co. Calcium channel blockers help relax arteries by selectively preventing movement of calcium ions across cell membranes of heart muscles and blood vessels without changing the amount of calcium in the blood

Federal health officials warned yesterday that a drug prescribed to treat high blood pressure and heart disease should be used 'with great caution, if at all' and that the safety of related drugs taken by millions of Americans was unclear. The warning from the National Heart, Lung and Blood Institute applied specifically to large doses of the short-acting form of nifedipine, which is marketed as Procardia by Pfizer Inc. and as Adalat by Bayer Co. The heart institute, a unit of the National Institutes of Health in Bethesda, Md., stopped short of extending the warning to all calcium channel blockers